The activation of this pathway may result from increased signaling due to the overexpression of ligands (i.e., EGF, IGF1 and IGF2) or from mutations in PI3KCA or PTEN. Certain cancer patients can have a simultaneous activation of AKT. This evidence concerns the gene EGF and cancer.